LEESBURG, Va., June 9, 2014 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (Nasdaq:KTWO) (the "Company" or "K2M"), a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine technologies, techniques and minimally invasive procedures, today announced that the underwriters for the Company's initial public offering exercised their option to purchase 1,000,000 shares of common stock from the selling stockholders at a price of $15.00 per share before underwriting discounts. The closing of the over-allotment option is expected to occur on June 10, 2014. K2M will not receive any proceeds from the sale of these shares.
Piper Jaffray & Co., Barclays Capital Inc. and Wells Fargo Securities, LLC acted as joint book-running managers for the offering. William Blair & Company, L.L.C. and Cowen and Company, LLC acted as co-managers.
The offering was made solely by means of a prospectus, copies of which may be obtained from Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, via telephone at 800-747-3924 or email at firstname.lastname@example.org; Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, via telephone at 888-603-5847 or email at Barclaysprospectus@broadridge.com; and Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, NY, 10152, via telephone at 800-326-5897 or email at email@example.com.
The registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission (the "SEC"). This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
K2M Group Holdings, Inc. is a global medical device company focused on designing, developing and commercializing innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most difficult and challenging spinal pathologies. K2M has leveraged these core competencies to bring to market an increasing number of products for patients suffering from degenerative spinal conditions. These technologies and techniques, in combination with a robust product pipeline, enable the company to favorably compete in the global spinal surgery market.
Certain statements made in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are based on management's expectations, estimates, projections, and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Additional information regarding these factors is contained in the Company's Registration Statement on Form S-1 filed with the SEC.
CONTACT: Investor Contact Westwicke Partners on behalf of K2M Group Holdings, Inc. Mike Piccinino, CFA or Mark Klausner 443-213-0500 K2M@westwicke.comSource:K2M Group Holdings, Inc.